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Summary
Objective: Non-opioid analgesics (NOAs) are widely used to palliate osteoarthritis (OA) pain, however, their role in health-related quality of life
(HRQoL) in OA has not been well studied. Here, we assess the relationship of pain, physical function, and HRQoL to NOA use in symptomatic
knee OA.
Methods: NOA dose, pain, physical function, and HRQoL were evaluated longitudinally over 1 year in medial knee OA. Doses provided by
subjects’ weekly medication diaries were normalized to equi-analgesic ibuprofen-equivalents (IEs). Descriptive analyses at baseline, 1.5,
and 12 months, and non-parametric comparisons of NOA with pain, physical function, and HRQoL at 1.5 months and over 12 months
were performed.
Results: Seventy-one subjects (19 males and 52 females; mean 57 10.5 years) used an overall median of 300 mg/week of IE. Twenty-ﬁve
subjects reported no analgesic use during the study; of the 46 subjects that reported NOA use, the median intake was 1325 mg/week IE.
Whereas age, Physical Functioning (PF) and HRQoL were predictive of NOA dose both at 1.5 months and during the entire study, pain level
was not. The median NOA dose declined over 12 months (P¼ 0.02), however, the change was not associated with changes in PF, HRQoL or
pain.
Conclusion: Greater age and worse physical function and HRQoL, but not pain severity, are predictive of NOA use in symptomatic knee OA.
Longitudinally, NOA use does not change as a function of pain. These data suggest that pain is not the primary determinant of NOA use over
time among OA patients.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Non-opioid analgesics (NOAs), such as the non-steroidal
anti-inﬂammatory agents (NSAIDs), the coxibs, and acet-
aminophen have varied anti-inﬂammatory and analgesic
properties and are widely used to palliate the pain of oste-
oarthritis (OA). However, despite the availability and usage
of a variety of these agents, OA patients continue to suffer
chronic pain and a diminished health-related quality of life
(HRQoL), and the morbidity related to OA remains
substantial.
To date the relationships between the use of such anal-
gesic agents and pain, functional status, and quality of life
in patients with OA have not been evaluated with controlled
trials. It has previously been suggested that patients with
relatively good Physical Functioning (PF) may not require
regular analgesic therapy, and that relief obtained with an-
algesic medication may be a more signiﬁcant indicator of
quality of life than of pain levels in patients with OA1.
OA patients may be started on analgesics for the indica-
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1294inadvertently continue the regular use of these prescriptions
despite their pain having improved or abated. In this study,
we assessed the relationship between demographics, pain
severity, PF, and HRQoL as predictor variables for contin-
ued NOA use in patients with symptomatic knee OA, to
test the hypothesis that NOA use correlates more closely
with indices of well-being than with pain in knee OA.Methods
Subjects were recruited as part of an ongoing, randomized, double-blind,
placebo-controlled, 3-year longitudinal assessment of a biomechanical inter-
vention for knee OA (ClinicalTrials.gov, NCT00076453) to study the clinical
effects of altered biomechanics in knee OA. The biomechanical intervention
under investigation in the primary study is a custom fabricated laterally
wedged orthotic shoe insert, which is compared in a double-blind random-
ized manner to a neutral orthotic insert; the primary outcomes to be
assessed are dynamic loading of the medial knee and pain reduction at 3
years.
After approval by the Institutional Review Board and provision of informed
consent, subjects were included if they had symptomatic knee OA deﬁned
both radiographically  grades 2 or 3 OA based on the Kellgren and
Lawrence scale2, as modiﬁed by Felson et al.3, and symptomatically  at
least 20 mm (of a 100 mm visual analog scale) of knee pain while walking
on a level surface, corresponding to question #1 of the Western Ontario
and MacMaster Universities OA Index (WOMAC)4. Each subject fulﬁlled the
American College of Rheumatology criteria for the classiﬁcation of knee
OA5 and had predominantly medial compartment involvement. Subjects
were excluded if they had clinically evident OA involving lower extremity joints
other than the knees, if they had any inﬂammatory arthropathy or other signif-
icant medical disease, or if they had a body mass index (BMI)> 35 kg/m2; in
addition, as the study group was recruited primarily for a biomechanical study,
Table I
Baseline pain, physical function, and HRQoL scores
Health parameters Median (IQR)
HAQ
Global 0.6 (0.2, 1.0)
Pain 0.9 (0.4, 1.2)
DI 0.5 (0.3, 0.8)
SF-36
BP 57.5 (45, 67.5)
GH 75 (60, 85)
1295Osteoarthritis and Cartilage Vol. 16, No. 11subjects with prior arthroplasty of any lower extremity joint were excluded.
The purpose of the primary study was to characterize biomechanical alter-
ations, and the study was explicitly designed not to interfere with the normal
OA care provided to these patients by their rheumatologists. Therefore, there
were no speciﬁc instructions concerning the use of analgesics, except that
any use was to be documented in the diaries and at the study visits. The
use of complementary and alternative medicine was not excluded but was
not to vary during the study period. In addition, hyaluronans were not permit-
ted within 6 months of enrollment, physiotherapy and exercise programs were
permitted but the regimen was not to change during the study, and weight was
tracked. At each study visit (at baseline, and months 1.5, 3, 6, 9, and 12), sub-
jects underwent medical histories and physical examinations, and completed
the standardized questionnaires.Mental Health (MH) 78 (68, 88)
PF 60 (45, 80)
Role Emotional (RE) 100 (67, 100)MEDICATION USE
RP 50 (0, 100)
Social Functioning (SF) 80 (68, 100)
V 60 (50, 70)
MCS 76.5 (63.8, 85.3)
PCS 62.5 (46.3, 74.4)
WOMAC
ADL 610 (368, 823)
Stiffness 86 (28, 124)
Pain 181 (97, 281)
HAQ: Global Assessment, Pain, DI; score range 0 (best)e3
(worst). SF-36: BP, GH, MH, PF, RE, RP, SF, V, MCS, PCS; score
range 0 (worst) to 100 (best). WOMAC: ADL, score range
0 (best)e1700 (worst); Stiffness, score range 0 (best)e200 (worst);
Pain, score range 0 (best)e500 (worst).Medications taken by each subject at entry were recorded directly from
their prescription bottles and by questioning regarding over-the-counter med-
ications and dietary supplements. To determine medication use during the
ﬁrst year, subjects were each given a medication diary at study entry.
They were instructed to record on a weekly basis any analgesic use for
knee pain. If pain medication was used for an indication other than knee
pain, it was not included in the patient’s total use of pain medication. In ad-
dition to the medication diaries, subjects were asked about medication and
dosage changes at each of the visits during the 12-month follow-up. For
each subject, the medication intake was determined by averaging the weekly
medication usage during the course of the 12-month study period, and then
normalizing to equi-analgesic doses of ibuprofen6. These values were then
expressed as total mg ibuprofen-equivalents (IEs) per week. Subjects for
whom medication diaries were unavailable or were incomplete were ex-
cluded from the analyses. All of the data were collected for this study during
the ﬁrst year of participation of each subject, in the 3-year longitudinal inter-
vention study for knee OA. The values are all expressed as total medication
per week (IEs/week). As subjects did not initiate their use of the medication
diaries until the baseline visit, it was not possible to accurately quantify the
medication taken in the week prior to baseline. Therefore, the month 1.5 visit
was used for the early timepoint in the analyses. Follow-ups at 6 weeks (1.5
months) and 12 months were prospectively chosen as primary endpoints and
those data are reported.ASSESSMENT OF PAIN, PHYSICAL FUNCTION AND HRQoLHealth outcome measures of interest were pain, physical function and
HRQoL. These were assessed using the Health Assessment Questionnaire
(HAQ)7, the Short Form-36 (SF-36)8, and the WOMAC4 at study entry, 1.5
months and at 12 months. All three tools include validated assessments of
pain, physical function, and HRQoL.STATISTICAL ANALYSESDescriptive statistics of the study subjects and their NOA use, and health
outcome measures of pain, physical function, and HRQoL were obtained.
The data were tested for normality. A non-parametric test, the KruskalleWal-
lis test, was utilized to compare the average NOA dose per week at 1.5
months and over the year as a function of the subjects’ study entry and
12-month measures of pain, physical function, and HRQoL, taking
P< 0.05 as signiﬁcant using a two-tailed test.Results
A total of 71 subjects (19 males and 52 females), with
a mean S.D. age of 57 10.5 years participated. The ma-
jority of the subjects were either African American (46.5%)
or Caucasian (38%). The mean S.D. BMI of the study
group was 30.1 6.5 kg/m2. The overall median scores
[and interquartile ranges (IQRs)] at baseline for pain, phys-
ical function, and HRQoL, using the HAQ, SF-36, and
WOMAC are presented in Table I. During the course of
the study, the median (IQR) intake of NOAs was 300 mg/
week of IEs (0, 3147 mg/week); however, 25 subjects re-
ported that they did not take any analgesics during the
study period at all. As a large number of subjects reported
medication intake as zero and the data set did not have
a normal distribution, the medication dose data were di-
vided into approximate tertiles for the purposes of analysis:zero intake of NOA, between zero and the median intake of
the remaining subjects, and greater than the median intake.
One-third (n¼ 25, 35.2%) of the participants did not use any
NOA despite a diagnosis of symptomatic knee OA at study
entry, another one-third (n¼ 23, 32.4%) of the participants
used between 0 and 1325 mg/week of IE, and the remain-
ing 23 subjects (32%) used 1325 mg/week or higher of IE
over the study duration for their knee OA.
Analysis of the three groups of NOA intake revealed that
they had similar gender and BMI distributions (Table II),
however, the subjects who used more than 1325 mg/week
of NOA over the year were older (mean 62.9 10.5 years)
than those who used either no NOA (55.2 9.9 years) or
between 0 and 1325 mg/week of NOA (54.3 9.4 years),
P¼ 0.02. Age did not correlate with pain [SF-36 Bodily
Pain (BP), Pain HAQ, WOMAC pain] or with physical func-
tion [PF, WOMAC Activities of Daily Living (ADL), global
HAQ or HAQ Disability Index (DI)], but did correlate with
HRQoL [Physical Component Score (PCS) (r¼0.32,
P¼ 0.008) and General Health (GH) (r¼0.25, P¼ 0.04)].
Importantly, there was no association between baseline
pain severity and quantity of NOA use, as assessed by
any of the validated pain scales [HAQ Pain (P¼ 0.45),
SF-36 BP score (P¼ 0.55), and WOMAC Pain subscale
(P¼ 0.68)], as shown in Table II. In addition there was no
association between 1.5 months or 12 months pain severity
and quantity of NOA used at either the 1.5 months visit or
over the 12 months study duration [HAQ Pain (P¼ 0.17
and 0.54, for 1.5 months and 12 months, respectively),
SF-36 BP score (P¼ 0.07 and 0.29, respectively), and WO-
MAC Pain subscale (P¼ 0.15 and 0.56, respectively)], as
shown in Table III.
Evaluation of the parameters of physical function and
HRQoL, however, revealed that these domains were
strongly associated with the quantity of NOA used by sub-
jects during the 12-month study period. At baseline, those
subjects with the most disability, as measured by the
Table II
Medication use and demographics and baseline health scores
Demographic and health parameters No medication <1325 mg/week* >1325 mg/week* P-Value
Age (years) (expressed as mean S.D.) 55.2 9.9 54.3 9.4 62.9 10.5 0.02y
Race
Black 11 (44%) 10 (44%) 11 (50%) 0.87
White 11 (44%) 8 (35%) 8 (36%)
Other 3 (12%) 5 (21%) 3 (14%)
Gender
Male 5 (20%) 7 (30%) 7 (30%)
Female 20 (80%) 16 (70%) 16 (70%)
BMI (kg/m2) 28.6 3.6 29.4 4.5 32.3 9.5 0.32
HAQ
Global [expressed as median (IQR)] 0.7 (0.4, 1.0) 0.5 (0.2, 1.0) 0.7 (0.2, 1.1) 0.77
Pain 0.9 (0.3, 1.1) 0.8 (0.4, 1.1) 0.9 (0.5, 1.4) 0.45
DI 0.5 (0.3, 0.8) 0.4 (0.1, 0.6) 0.6 (0.5, 0.9) 0.01y
SF-36
BP 58 (45, 74) 58 (47, 68) 58 (40, 68) 0.55
GH 81 (65, 90) 75 (65, 88) 65 (55, 75) 0.02y
MH 80 (70, 88) 76 (60, 85) 76 (68, 88) 0.78
PF 65 (50, 79) 67 (45, 85) 55 (35, 65) 0.07
RE 100 (100, 100) 100 (25, 100) 100 (33, 100) 0.22
RP 67 (0, 88) 75 (25, 100) 13 (0, 75) 0.03y
SF 90 (78, 100) 78 (68, 100) 78 (60, 100) 0.11
V 65 (53, 75) 60 (49, 70) 55 (50, 65) 0.20
MCS 79.9 (68.7, 89.9) 75.8 (58.4, 85.3) 73.4 (55.5, 80.6) 0.08
PCS 63.3 (47.7, 73.5) 66.6 (56.9, 80.6) 50.0 (35.0, 63.1) 0.02y
WOMAC
ADL 484 (258, 699) 687 (368, 802) 786 (450, 1090) 0.15
Stiffness 80 (34, 124) 74 (14, 123) 97 (31, 130) 0.40
Pain 152 (81, 279) 195 (119, 281) 217 (94, 282) 0.68
*Medication intakes are expressed in IE doses (see text for explanation).
ySigniﬁcant P-value.
Table III
Correlation of medication with health outcome measures (month
1.5)
Health outcome measure Medication use,
correlation (P)
Yearly average
medication,
correlation (P)
HAQ
Global 0.19 (0.11) 0.14 (0.26)
Pain 0.17 (0.17) 0.08 (0.54)
DI 0.14 (0.25) 0.11 (0.39)
SF-36
BP 0.22 (0.07) 0.13 (0.29)
GH 0.22 (0.07) 0.27 (0.03)*
MH 0.04 (0.78) 0.01 (0.91)
PF 0.28 (0.02)* 0.22 (0.07)
RE 0.10 (0.40) 0.13 (0.30)
RP 0.25 (0.04)* 0.12 (0.32)
SF 0.14 (0.24) 0.11 (0.36)
V 0.02 (0.85) 0.01 (0.93)
MCS 0.09 (0.45) 0.08 (0.49)
PCS 0.31 (0.01)* 0.23 (0.06)
WOMAC
ADL 0.18 (0.13) 0.20 (0.10)
Stiffness 0.21 (0.09) 0.10 (0.40)
Pain 0.17 (0.15) 0.07 (0.56)
Expressed as Spearman’s rank coefﬁcient (P-value).
*Signiﬁcant P-value.
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study duration relative to those with less disability
(P¼ 0.01). Similar results were also observed with the
SF-36 physical function and HRQoL subscales, whereas
those who scored poorer on the PCS, GH, and Role Phys-
ical (RP) used signiﬁcantly more NOA than their peers who
scored better in each category, P¼ 0.02, 0.02, and 0.03, re-
spectively. In addition, there was a comparable trend for the
SF-36 Mental Component Score (MCS), P¼ 0.08 (Table II).
An inverse relationship between NOA dose at 1.5 months
and PF (P¼ 0.02), RP (P¼ 0.04) and PCS (P¼ 0.01) was
observed. Similarly, the yearly NOA dose was inversely
associated with GH (P¼ 0.02) at 1.5 months (Table III).
Subgroup analyses were performed on the 46 subjects
who reported some medication use (not zero) during the
study period. Using the sub-sample size of 46 and the pre-
viously determined standard errors, there was 80% power
to detect correlations as small as 0.399; even using a t
test with equal group sizes, there would be 80% power to
detect effect sizes of 0.89. The median (IQR) medication in-
take in this subpopulation was 1325 mg/week (325,
6650 mg/week) of IE. Spearman’s rank correlation coefﬁ-
cients (r) between the NOA weekly dose for these 46 sub-
jects with some NOA use over the year and pain, physical
function, and HRQoL are shown in Table IV. As with the
total study group, there was no correlation in any of the
pain subscales between baseline pain levels and total med-
ication intake, even among those subjects who actually
used NOA: HAQ Pain, r¼ 0.11, P¼ 0.49; SF-36 BP,
r¼0.19, P¼ 0.21; WOMAC Pain, r¼0.002, P¼ 0.99
(Table IV). In contrast, there was a signiﬁcant correlation
Table V
Correlation between changes in medication dose and health
outcome measures between month 1.5 and month 12
Parameter Month 1.5
(meanS.D.)
Month 12
(meanS.D.)
P-Value
HAQ
Global 0.51 0.44 0.38 0.34 0.16
Pain 0.62 0.54 0.55 0.51 0.66
DI 0.45 0.42 0.44 0.46 0.99
BP 64.1 18.6 71.4 17.7 0.04*
SF-36
GH 72.9 16.3 72.2 19.0 0.97
MH 65.1 8.3 64.8 8.0 0.84
PF 65.9 23.6 67.9 22.4 0.92
RE 75.7 36.3 79.0 34.3 0.44
RP 67.9 38.3 67.7 36.6 0.99
SF 83.0 18.5 85.0 16.9 0.36
V 55.7 9.5 53.7 10.4 0.69
MCS 69.9 13.7 70.6 12.0 0.52
PCS 67.5 19.0 69.6 18.7 0.91
WOMAC
ADL 390 391 289 370 0.004*
Stiffness 44.6 45.5 30.6 42.3 0.01*
Pain 106 116 77 102 0.01*
NSAID dosey 3262 7198 2013 4863 0.02*
*Signiﬁcant P-value.
yExpressed in mg of IE doses.
Table VI
Correlation between change in medication dose and changes in
health outcome measures (month 1.5emonth 12)
Health outcome measure Change in medication,
correlation (P-value)
HAQ
Global 0.04 (0.74)
Pain 0.008 (0.95)
DI 0.01 (0.93)
SF-36
BP 0.06 (0.66)
GH 0.008 (0.95)
MH 0.10 (0.46)
PF 0.09 (0.50)
RE 0.04 (0.77)
RP 0.05 (0.72)
SF 0.06 (0.62)
Table IV
Correlation of demographics, health outcome measures and medi-
cation use
Parameter Spearman’s rank
correlation (r) with dose
P-Value
Age 0.42 0.004*
BMI 0.02 0.90
HAQ
Global 0.06 0.70
Pain 0.11 0.49
DI 0.40 0.006*
SF-36
BP 0.19 0.21
GH 0.35 0.02*
MH 0.03 0.85
PF 0.30 0.04*
RE 0.03 0.87
RP 0.48 0.001*
SF 0.05 0.76
V 0.13 0.39
MCS 0.02 0.90
PCS 0.45 0.002*
WOMAC
ADL 0.10 0.51
Stiffness 0.10 0.49
Pain 0.002 0.99
Subgroup analysis of the 46 subjects who took NOA during the
study.
*Signiﬁcant P-value.
1297Osteoarthritis and Cartilage Vol. 16, No. 11between NOA dose and age (r¼ 0.42, P¼ 0.004), as well
as NOA dose predicted by baseline physical function and
HRQoL indices: HAQ DI, r¼ 0.40, P¼ 0.006; SF-36 GH,
r¼0.35, P¼ 0.02; SF-36 physical function r¼0.30,
P¼ 0.04; SF-36 RP r¼0.48, P¼ 0.001; SF-36 PCS,
r¼0.45, P¼ 0.002.
Longitudinal analysis revealed that there were signiﬁcant
improvements in mean (S.D.) pain scores during the
course of the 12 months, as measured by SF-36 BP,
64.1 18.6 vs 71.4 17.7 (P¼ 0.04), and WOMAC Pain,
106 116 vs 77 102 (P¼ 0.01), subscales at 1.5 months
and 12 months, respectively (Table V). Aside from the WO-
MAC stiffness (P¼ 0.01) and WOMAC ADL (P¼ 0.004)
subscales, there was no signiﬁcant variability in the other
HRQoL and physical function scores over time. In addition,
there was a signiﬁcant reduction in mean (S.D.) medica-
tion use (expressed as IEs) by month 12, 3262 7198 vs
2013 4863 (P¼ 0.02).
Despite the signiﬁcant reductions both in pain scores and
in medication intake over time, there was neither signiﬁcant
association between medication dose and pain at month
1.5, nor was there an association between change in med-
ication dose and change in pain scores by month 12 [HAQ
Pain (P¼ 0.95), SF-36 BP score (P¼ 0.66), and WOMAC
Pain subscale (P¼ 0.29)] (Table VI and Fig. 1). In addition,
there was no association between changes in NOA intake
and changes in physical function or HRQoL.V 0.10 (0.46)
MCS 0.01 (0.97)
PCS 0.03 (0.80)
WOMAC
ADL 0.13 (0.30)
Stiffness 0.05 (0.70)
Pain 0.13 (0.29)Discussion
The results of this study suggest that although analgesics
are generally prescribed to palliate pain, OA patients’ actual
use of these agents may relate more to their general level of
PF and quality of life than to their current pain or change inpain. In fact, functional status and quality of life appear to be
predictors of analgesic use in patients with OA; greater use,
especially among older individuals, may be a surrogate of
reduced PF, or lower HRQoL. Thus, whereas analgesics
and anti-inﬂammatory medications are generally prescribed
by physicians and medical care providers speciﬁcally to pal-
liate pain, these data suggest that patients may actually em-
ploy these medications for reasons other than pain relief.
There may be several reasons why patients utilize NOAs
for indications unrelated speciﬁcally to pain palliation. For
Fig. 1. The lack of correlation between changes in NOA dose, ex-
pressed as IEs per week, and the change in pain (using the HAQ).
1298 S. Mody et al.: HRQoL, pain, and analgesia use in knee OAexample, these medications may relieve joint stiffness and
thereby improve physical function. However, no association
between change in NOA dose with change in stiffness (as
measured by WOMAC stiffness), or physical function (WO-
MAC ADL) was observed over the study duration. Some pa-
tients may continue taking regular doses of NOA after pain
has abated either because they do not realize that these
medications may be discontinued or they do not recall the
speciﬁc indication for which the medication was initiated.
Thus, although physicians may intend NOA to be used
only intermittently for relief of painful exacerbations of OA,
patients may continue taking prescribed medications until
explicitly counseled to stop; this suggests that at the time
of initiating therapy, patients should be carefully educated
regarding the appropriate use and discontinuation of NOA
in OA. Finally, there may be unrelated pharmacological ef-
fects of these medications that may result in improved qual-
ity of life through as yet undescribed mechanisms.
Nonetheless, the observation that the quantity of analgesic
medication consumed by OA patients cross sectionally and
over a 12-month period is predicted better by their state of
physical function and HRQoL than by their pain level should
be considered by practitioners when prescribing and con-
tinuing these medications.
NOA use may have declined during the study period
for a variety of reasons, such as a placebo effect from
the primary intervention study, which included several
study visits, or other unmeasured variables (including
the biomechanical intervention) or a change in HRQoL.
A signiﬁcant decrease in WOMAC ADL, pain and stiff-
ness scores was observed as well as a decrease in total
NOA usage, however, the change in NOA did not corre-
late with the changes in WOMAC ADL, pain or stiffness
(Table VI). If the decreased NOA use was due to the bio-
mechanical intervention, then a relationship between
change in NOA and change in pain should have been
observed.
Another limitation of this study was that a signiﬁcant
number of the subjects (>33%) did not use any analgesic
medications at all; this may have been a result of the na-
ture of the study, as biomechanical interventions may have
special appeal to individuals who do not wish to take oral
medications. This limitation was addressed throughsubgroup analysis of those subjects who did use analge-
sics, based on medication dose, and the results were
similar.
The strengths of this study include its generalizability.
The participants were not primed by the investigators about
any aspect of NOA use, and were unaware of this study
goal at the time of their study visit; in addition, it was not
a medication study. Hence, the results may better represent
the actual pattern of NOA use by OA patients in practice,
because they are devoid of responder and acquiescence
bias. Furthermore, the study subjects were in relatively
good health without substantial co-morbidities, thus avoid-
ing the confounding nature of NOA use for extraneous indi-
cations. As a result, the patterns of NOA use in this study
may be ascribed to OA, and the results may provide novel
insights into NOA use for OA.
The results of this study suggest that among knee OA
patients, analgesic intake may not be solely related to is-
sues of pain; moreover, among OA patients with increased
disability or poorer HRQoL, the use of pain medications
may be related more to these reasons than to the need
for pain relief. Our results indicate the need for physicians
to periodically review indications and to educate patients
about continued use of NOA, especially in the geriatric pop-
ulation. Further studies, including larger group sizes and
employing qualitative patient interviewing are necessary
to fully elucidate the roles of physical function, quality of
life, and feelings of well-being in the decision of OA
patients to employ continued analgesia in their care, and
thereby to improve the management of analgesic therapy
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